WANBURY LTD.

Wanbury Ltd has announced a book closure period from Friday, September 18, 2026, to Thursday, September 24, 2026, inclusive. This closure is for the purpose of the company's 38th Annual General Meeting (AGM). The AGM is scheduled to be held on Thursday, September 24, 2026, at 11:30 AM via Video Conferencing (VC)/Other Audio Visual Means (OAVM). The notice complies with Section 91 of the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Wanbury Limited has announced its 38th Annual General Meeting (AGM) to be held on Thursday, September 24, 2026, at 11:30 AM via Video Conferencing (VC)/Other Audio Visual Means (OAVM). The company is submitting its Annual Report for the financial year 2025-26 along with the Notice of AGM, as per SEBI regulations. The AGM will cover ordinary business such as adopting the audited financial statements and appointing a director, as well as special business including ratifying the remuneration for the Cost Auditor for FY 2026-27. The Annual Report is available on the company's website.

Wanbury Ltd. has issued a notice for its 38th Annual General Meeting (AGM) scheduled for Thursday, September 24, 2026, at 11:30 A.M. The meeting will be conducted entirely through Video Conferencing (VC) or Other Audio Visual Means (OAVM). The company is also submitting its Annual Report for the financial year 2025-26, which includes the AGM notice, to the stock exchange and has made it available on its website. The agenda includes adopting the audited financial statements for FY26, re-appointing a director retiring by rotation, and ratifying the remuneration of the cost auditor for FY27.

Wanbury Limited has announced significant regulatory milestones. The company received approval from the European Directorate for the Quality of Medicines and Healthcare (EDQM) for its new product, Rivaroxaban API. This approval will allow Wanbury to meet customer demands within the EU and other countries that accept CEP (Certificate of Suitability to the monographs of the European Pharmacopoeia). Additionally, Wanbury has obtained Drug Master File (DMF) clearances from the US Food and Drug Administration (USFDA) for Paraxetine HCI and Metformin HCI. The company is also undergoing ANDA (Abbreviated New Drug Application) reviews for multiple customers, indicating further growth prospects in international markets.

Wanbury Limited reported its un-audited financial results for the quarter ended June 30, 2026. Revenue from operations increased by 1.5% YoY to ₹165.6 crore, but was impacted by logistics disruptions due to the West Asia crisis. Gross profit declined to ₹86.9 crore, with margins contracting to 52.5% due to a sudden increase in raw material prices. EBITDA fell 33.0% to ₹16.6 crore, and Profit After Tax (PAT) dropped 76.0% to ₹3.2 crore. The company completed a debt refinancing, reducing borrowing costs to below 10% and freeing promoter shares from pledge. Regulatory approvals were received from TGA Australia and MFDS Korea, and DMFs were filed for new markets. The company expects benefits from a new manufacturing block in upcoming quarters.

Wanbury Ltd announced the outcome of its Board Meeting held on August 11, 2026. The Board approved the Un-audited Financial Results for the first quarter and three months ended June 30, 2026. Additionally, the Board approved the allotment of 27,530 equity shares under the ESOP 2016 plan, increasing the paid-up share capital. The re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director for a term of five years, effective August 21, 2026, was also approved, subject to member and regulatory approvals.

Wanbury Ltd announced the outcome of its Board Meeting held on August 11, 2026. The Board approved the Un-audited Financial Results for the first quarter and three months ended June 30, 2026. Additionally, the company approved the allotment of 27,530 equity shares under the Wanbury Limited Employee Stock Option Plan 2016. The paid-up share capital will increase following this allotment. The Board also approved the re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director for a term of five years, effective August 21, 2026, subject to member and regulatory approvals.

Wanbury Limited announced that its Board of Directors, in a meeting held on August 11, 2026, has approved the unaudited financial results for the first quarter and three months ended June 30, 2026. The company also approved the allotment of 27,530 equity shares under its ESOP 2016 plan, increasing its paid-up share capital. Additionally, the Board approved the re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director for a five-year term, effective August 21, 2026, subject to member and regulatory approvals. The results will be available on the company's website.

Wanbury Ltd has announced that its Board of Directors will convene on August 11, 2026, to consider and approve the Un-audited Financial Results for the first quarter and three months ended June 30, 2026. In line with SEBI regulations, the company has also informed about the closure of the trading window for its Directors, Officers, Key Managerial Personnel, and Designated Employees. This window will remain shut until 48 hours after the declaration of the financial results. The company has made this information available on its website and the BSE and NSE websites.

Wanbury Limited has announced that it has received a "No DMF deficiency letter" from the US Food and Drug Administration (USFDA) for multiple Abbreviated New Drug Applications (ANDAs). This pertains to the Metformin HCl API source supplied by Wanbury for various formulations. The company also noted its expansion into the South Korean market for another API, for which a Drug Master File (DMF) has been filed. Wanbury reaffirms its commitment to supplying high-quality APIs for human well-being.